Single Nucleotide Polymorphism (SNP) Genotyping Market Revenue to Attain USD 34.78 Bn by 2033

Published: 21 Nov 2025

Author: Precedence Research

Share :

Table of Content

1. Single Nucleotide Polymorphism (SNP) Genotyping Market Revenue and Trends 2025 to 2033 2. What are the key drivers enabling the growth of this market? 3. Segment Insights 4. Regional Insights 5. Single Nucleotide Polymorphism (SNP) Genotyping Market Coverage

Single Nucleotide Polymorphism (SNP) Genotyping Market Revenue and Trends 2025 to 2033

The global single nucleotide polymorphism (SNP) genotyping market revenue surpassed USD 7.52 billion in 2025 and is predicted to attain around USD 34.78 billion by 2033, growing at a CAGR of 21.10%. The market is rising due to the accelerating adoption of precision medicine, expanding genomic research investments, and rapid technological advancements enabling affordable, high-throughput SNP detection.

What are the key drivers enabling the growth of this market?

The Single Nucleotide Polymorphism (SNP) Genotyping Market is gaining significant momentum as health care systems emphasize precision diagnostics and deepen insights into the genetic underpinnings of disease susceptibility. Additionally, the growing use of genomic tools for drug discovery and personalized therapies is driving the need for scalable, accurate SNP Genotyping platforms.

Likewise, the growing landscape of population genetics, biobanking initiatives, and clinical research is allowing for broader acceptance of the technology. The lower cost of high-throughput genotyping and the utilization of advanced molecular technologies make SNP testing even more readily available in research and clinical settings. To broaden global access to SNP genotyping, many collaborations are emerging among biopharma companies, genomic labs, and academic organizations.

Segment Insights

• By Technology, the PCR-based genotyping segment dominated the market in 2024, due to its high sensitivity, cost efficiency, and applicability to different types of samples, which make it a method of choice for clinical testing and large-scale research programs.
• By Product/Component, the instruments segment dominated the market as laboratories shift toward automated, high-throughput genotyping systems to support automation, operational efficiency, throughput in healthcare, and objectivity for more genomics and disease characterization research
• By Application, the pharmaceuticals and pharmacogenomics segment dominates the market, since it plays an important role (the two most important roles) for identifying genetic markers, optimizing therapeutic response, is associated with avoiding adverse drug effects, and has implications for accelerating drug discovery and drug development strategies.
• By End User, the pharmaceutical and biotechnology companies segment has dominated the market, with biomarker identification and precision medicine for the purpose of producing or accelerating research outcomes, using precision medicine within the treatment environment.

Regional Insights

North America has the largest market share, owing to some of the best-funded genomics-related infrastructure in the world, high levels of R&D investment, and the strong uptake of a range of cutting-edge molecular diagnostics applications. Supported by government initiatives and activity in the biotechnology space, the region's preeminence and application base continue to strengthen.

The Asia-Pacific region is growing rapidly, driven by factors including increased funding for genomics and population-scale genetic investigations, and the growing adoption of precision medicine. As the biotechnology landscape evolves across many emerging markets, advances in technology will similarly promote market penetration.

Single Nucleotide Polymorphism (SNP) Genotyping Market Coverage

Recent Developments

• In March 2024, Thermo Fisher Scientific launched its upgraded Axio Precision Medicine Arrays, offering improved SNP detection sensitivity and broader ancestry coverage. The new system supports advanced biomarker discovery and drug response analysis.(Source: https://biopharmaapac.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7125

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344